天臣医疗：预计2025年全年归属净利润盈利8289.48万元至8889.48万元

Core Viewpoint - Tianchen Medical forecasts a net profit attributable to shareholders of 82.89 million to 88.89 million yuan for the full year of 2025, driven by innovation and stable sales growth in its product matrix [1] Financial Performance - For the first three quarters of 2025, the company's main revenue reached 244 million yuan, an increase of 20.66% year-on-year [1] - The net profit attributable to shareholders for the same period was 71.95 million yuan, reflecting a year-on-year increase of 68.29% [1] - The net profit after deducting non-recurring gains and losses was 66.20 million yuan, up 71.85% year-on-year [1] Quarterly Performance - In Q3 2025, the company's main revenue was 87.66 million yuan, representing a year-on-year increase of 26.4% [1] - The net profit attributable to shareholders for Q3 was 23.73 million yuan, showing a year-on-year increase of 70.74% [1] - The net profit after deducting non-recurring gains and losses for Q3 was 21.92 million yuan, up 72.61% year-on-year [1] Operational Metrics - The company's debt ratio stands at 11.3% [1] - Investment income reported was 2.56 million yuan [1] - Financial expenses were recorded at -10.87 million yuan, with a gross profit margin of 63.22% [1]